Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,492,971	$ 1,550,004
Accounts receivable, net	167,256	131,544
Accounts receivable - related parties	3,814	4,598
Inventory, net	8,697	3,362
Prepaid expenses and other current assets	33,094	33,537
Total current assets	1,705,832	1,723,045
Property and equipment, net	149,171	145,770
Investments	103,031	102,037
Equity method investments	8,207	13,194
Intangible assets, net	20,829	21,642
Goodwill	21,040	21,312
Other non-current assets	49,616	43,990
Total Assets	2,057,726	2,070,990
Current liabilities:
Accounts payable	35,257	8,189
Deferred revenue (includes $8,203 and $12,502 from related parties)	35,232	33,240
Accrued expenses and other current liabilities	88,758	93,332
Total current liabilities	159,247	134,761
Non-current liabilities:
Deferred rent, net of current portion	19,262	18,746
Deferred revenue, net of current portion (includes $143,037 and $148,319 from related parties)	170,176	155,991
Lease financing obligation	27,309	22,283
Warrant liabilities	50,803	135,838
Other non-current liabilities	16,881	35,992
Total Liabilities	443,678	503,611
Commitments and contingencies (Note 7)
Shareholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued	0	0
Common stock, $0.0001 par value (Note 5)	162	161
Additional paid-in capital	4,471,418	3,804,844
Accumulated deficit	(2,888,430)	(2,297,925)
Accumulated other comprehensive loss	(2,355)	(1,715)
Total Ginkgo Bioworks Holdings, Inc. stockholders equity	1,580,795	1,505,365
Non-controlling interest	33,253	62,014
Total stockholders equity	1,614,048	1,567,379
Total Liabilities and Shareholders' Equity	$ 2,057,726	$ 2,070,990